KRAS and non-small cell lung carcinoma: Previous reports indicated that DNA damage inducers enhanced the therapeutic efficacy in KRAS-mutated NSCLC, and notably the irinotecan (synthetic camptothecin derivate) showed potential effect against KRAS-mutated CRC and also been used towards metastatic PDAC in clinical settings (Canon et al., 2019; Liu et al., 2022; Formica et al., 2023).